Zimmer Biomet Reports Fourth Quarter and Full-Year 2016 Financial Results

Go back to Zimmer Biomet Reports Fourth Quarter and Full-Year 2016 Financial Results

Zimmer Biomet (ZBH) PT Raised to $132 at Oppenheimer Following 4Q Report

February 1, 2017 10:51 AM EST

Oppenheimer raised its price target on Zimmer Biomet (NYSE: ZBH) to $132.00 (from $126.00) while maintaining a Outperform rating.

Analyst Steven Lichtman commented, "4Q16 sales of $2.013B (+3.0% organic, ex-stocking/FX, day-adjusted) were in line with ZBH's above consensus pre-announcement earlier in January; recall Americas... More

Zimmer Biomet Holdings (ZBH) Tops Q4 EPS by 3c; Guides In-Line

January 31, 2017 7:34 AM EST

Zimmer Biomet Holdings (NYSE: ZBH) reported Q4 EPS of $2.14, $0.03 better than the analyst estimate of $2.11. Revenue for the quarter came in at $2.01 billion versus the consensus estimate of $1.98 billion.

GUIDANCE:

Zimmer Biomet Holdings sees FY2017 EPS of $8.50-$8.68, versus the consensus of... More